China Pharma Holdings (CPHI) Income from Continuing Operations (2010 - 2026)
China Pharma Holdings' (CPHI) quarterly Income from Continuing Operations came in at 1143148.0 in Q1 2026, down 45.52% YoY from 2098209.0 in Q1 2025, and up 6.46% on a QoQ basis from 1222135.0 in Q4 2025.
China Pharma Holdings (CPHI) Income from Continuing Operations (2010 - 2026) Analysis & Trends
China Pharma Holdings (CPHI) has 17 years of Income from Continuing Operations data on file, last reported at 1143148.0 in Q1 2026.
- Quarterly Income from Continuing Operations fell 45.52% year-over-year to 1143148.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 3545132.0 (up 22.36% YoY) and the FY2025 annual result came in at 2390666.0, up 32.7% from the prior year.
- Income from Continuing Operations advanced to 1143148.0 in Q1 2026, from 1222135.0 in the prior quarter.
- In the past five years, Income from Continuing Operations ranged from a high of 475976.0 in Q1 2023 to a low of 1438130.0 in Q2 2024.
- A 5-year average of 948160.47 and a median of 955892.0 in 2024 frame the typical range for Income from Continuing Operations.
- Annual changes were most pronounced in 2024 — Income from Continuing Operations plunged 142.51% — and 2025, when it jumped 63.26%.
- Tracing CPHI's Income from Continuing Operations over 5 years: stood at 1264184.0 in 2022, then climbed by 2.53% to 1232213.0 in 2023, then increased by 0.63% to 1224432.0 in 2024, then grew by 0.19% to 1222135.0 in 2025, then gained by 6.46% to 1143148.0 in 2026.
- The last three Income from Continuing Operations figures came in at 1143148.0 (Q1 2026), 1222135.0 (Q4 2025), and 651482.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.98 Bn | 43.02 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.28 Bn | 39.62 Bn | 2.15 Bn | -576.00 Mn |
| 3 | Zoetis | 31.79 Bn | 30.11 Bn | 1.05 Bn | 866.00 Mn |
| 4 | Takeda Pharmaceutical | 28.69 Bn | 22.89 Bn | 5.10 Bn | 1.33 Bn |
| 5 | United Therapeutics | 22.25 Bn | 19.58 Bn | 683.80 Mn | 333.00 Mn |
| 6 | Viatris | 18.75 Bn | 17.86 Bn | 1.46 Bn | -118.80 Mn |
| 7 | Neurocrine Biosciences | 15.58 Bn | 15.19 Bn | 935.80 Mn | 144.40 Mn |
| 8 | Elanco Animal Health | 11.87 Bn | 11.34 Bn | 798.00 Mn | 54.00 Mn |
| 9 | Dr Reddys Laboratories | 10.14 Bn | 9.98 Bn | - | - |
| 10 | China Pharma Holdings | 42.13 Mn | 41.82 Mn | 83,566.00 | -1.46 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -1.14 Mn |
| Dec 31, 2025 | -1.22 Mn |
| Sep 30, 2025 | -651,482.00 |
| Jun 30, 2025 | -528,367.00 |
| Mar 31, 2025 | -785,572.00 |
| Dec 31, 2024 | -1.22 Mn |
| Sep 30, 2024 | -1.12 Mn |
| Jun 30, 2024 | -1.44 Mn |
| Mar 31, 2024 | -955,892.00 |
| Dec 31, 2023 | -1.23 Mn |
| Sep 30, 2023 | -777,600.00 |
| Jun 30, 2023 | -593,029.00 |
| Mar 31, 2023 | -475,976.00 |
| Dec 31, 2022 | -1.26 Mn |
| Sep 30, 2022 | -790,773.00 |
| Jun 30, 2022 | -888,394.00 |
| Mar 31, 2022 | -1.03 Mn |
| Dec 31, 2021 | -980,719.00 |
| Sep 30, 2021 | -826,669.00 |
| Jun 30, 2021 | -824,761.00 |